Literature DB >> 26404963

The Association between Glyceraldehyde-Derived Advanced Glycation End-Products and Colorectal Cancer Risk.

So Yeon Kong1, Masayoshi Takeuchi2, Hideyuki Hyogo3, Gail McKeown-Eyssen4, Sho-Ichi Yamagishi5, Kazuaki Chayama3, Peter J O'Brien6, Pietro Ferrari1, Kim Overvad7, Anja Olsen8, Anne Tjønneland8, Marie-Christine Boutron-Ruault9, Nadia Bastide9, Franck Carbonnel10, Tilman Kühn11, Rudolf Kaaks11, Heiner Boeing12, Krasimira Aleksandrova12, Antonia Trichopoulou13, Pagona Lagiou14, Effie Vasilopoulou15, Giovanna Masala16, Valeria Pala17, Maria Santucci De Magistris18, Rosario Tumino19, Alessio Naccarati20, H B Bueno-de-Mesquita21, Petra H Peeters22, Elisabete Weiderpass23, J Ramón Quirós24, Paula Jakszyn25, María-José Sánchez26, Miren Dorronsoro27, Diana Gavrila28, Eva Ardanaz29, Martin Rutegård30, Hanna Nyström30, Nicholas J Wareham31, Kay-Tee Khaw32, Kathryn E Bradbury33, Isabelle Romieu1, Heinz Freisling1, Faidra Stavropoulou1, Marc J Gunter34, Amanda J Cross34, Elio Riboli34, Mazda Jenab35, W Robert Bruce36.   

Abstract

BACKGROUND: A large proportion of colorectal cancers are thought to be associated with unhealthy dietary and lifestyle exposures, particularly energy excess, obesity, hyperinsulinemia, and hyperglycemia. It has been suggested that these processes stimulate the production of toxic reactive carbonyls from sugars such as glyceraldehyde. Glyceraldehyde contributes to the production of a group of compounds known as glyceraldehyde-derived advanced glycation end-products (glycer-AGEs), which may promote colorectal cancer through their proinflammatory and pro-oxidative properties. The objective of this study nested within a prospective cohort was to explore the association of circulating glycer-AGEs with risk of colorectal cancer.
METHODS: A total of 1,055 colorectal cancer cases (colon n = 659; rectal n = 396) were matchced (1:1) to control subjects. Circulating glycer-AGEs were measured by a competitive ELISA. Multivariable conditional logistic regression models were used to calculate ORs and 95% confidence intervals (95% CI), adjusting for potential confounding factors, including smoking, alcohol, physical activity, body mass index, and diabetes status.
RESULTS: Elevated glycer-AGEs levels were not associated with colorectal cancer risk (highest vs. lowest quartile, 1.10; 95% CI, 0.82-1.49). Subgroup analyses showed possible divergence by anatomical subsites (OR for colon cancer, 0.83; 95% CI, 0.57-1.22; OR for rectal cancer, 1.90; 95% CI, 1.14-3.19; Pheterogeneity = 0.14).
CONCLUSIONS: In this prospective study, circulating glycer-AGEs were not associated with risk of colon cancer, but showed a positive association with the risk of rectal cancer. IMPACT: Further research is needed to clarify the role of toxic products of carbohydrate metabolism and energy excess in colorectal cancer development. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26404963      PMCID: PMC6284787          DOI: 10.1158/1055-9965.EPI-15-0422

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  60 in total

1.  Glyceraldehyde-derived advanced glycation end products in Alzheimer's disease.

Authors:  Hiroshi Choei; Nobuyuki Sasaki; Masayoshi Takeuchi; Taku Yoshida; Wataru Ukai; Sho-Ichi Yamagishi; Seiji Kikuchi; Toshikazu Saito
Journal:  Acta Neuropathol       Date:  2004-06-17       Impact factor: 17.088

Review 2.  Clinical review: The role of advanced glycation end products in progression and complications of diabetes.

Authors:  Su-Yen Goh; Mark E Cooper
Journal:  J Clin Endocrinol Metab       Date:  2008-01-08       Impact factor: 5.958

3.  Up-regulated expression of advanced glycation end-products and their receptor in the small intestine and colon of diabetic rats.

Authors:  Pengmin Chen; Jingbo Zhao; Hans Gregersen
Journal:  Dig Dis Sci       Date:  2011-11-06       Impact factor: 3.199

Review 4.  Emerging role of advanced glycation-end products (AGEs) in the pathobiology of eye diseases.

Authors:  Stylianos A Kandarakis; Christina Piperi; Fotis Topouzis; Athanasios G Papavassiliou
Journal:  Prog Retin Eye Res       Date:  2014-06-04       Impact factor: 21.198

Review 5.  Advanced glycation endproducts--role in pathology of diabetic complications.

Authors:  Nessar Ahmed
Journal:  Diabetes Res Clin Pract       Date:  2005-01       Impact factor: 5.602

Review 6.  Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.

Authors:  S Yamagishi; M Takeuchi; Y Inagaki; K Nakamura; T Imaizumi
Journal:  Int J Clin Pharmacol Res       Date:  2003

7.  Presence of glyceraldehyde-derived advanced glycation end-products in the liver of insulin-resistant mice.

Authors:  Yu Ebata; Junichi Takino; Hiroyuki Tsuchiya; Tomohiko Sakabe; Yoshito Ikeda; Susumu Hama; Kentaro Kogure; Masayoshi Takeuchi; Goshi Shiota
Journal:  Int J Vitam Nutr Res       Date:  2013       Impact factor: 1.784

8.  European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection.

Authors:  E Riboli; K J Hunt; N Slimani; P Ferrari; T Norat; M Fahey; U R Charrondière; B Hémon; C Casagrande; J Vignat; K Overvad; A Tjønneland; F Clavel-Chapelon; A Thiébaut; J Wahrendorf; H Boeing; D Trichopoulos; A Trichopoulou; P Vineis; D Palli; H B Bueno-De-Mesquita; P H M Peeters; E Lund; D Engeset; C A González; A Barricarte; G Berglund; G Hallmans; N E Day; T J Key; R Kaaks; R Saracci
Journal:  Public Health Nutr       Date:  2002-12       Impact factor: 4.022

9.  Advanced lipoxidation end-products mediate lipid-induced glomerular injury: role of receptor-mediated mechanisms.

Authors:  Carla Iacobini; Stefano Menini; Carlo Ricci; Angela Scipioni; Viola Sansoni; Giulia Mazzitelli; Samantha Cordone; Carlo Pesce; Francesco Pugliese; Flavia Pricci; Giuseppe Pugliese
Journal:  J Pathol       Date:  2009-07       Impact factor: 7.996

10.  Cigarette smoking and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition study.

Authors:  Anke M Leufkens; Fränzel J B Van Duijnhoven; Peter D Siersema; Hendriek C Boshuizen; Alina Vrieling; Antonio Agudo; Inger T Gram; Elisabete Weiderpass; Christina Dahm; Kim Overvad; Anne Tjønneland; Anja Olsen; Marie-Christine Boutron-Ruault; Françoise Clavel-Chapelon; Sophie Morois; Domenico Palli; Sara Grioni; Rosario Tumino; Charlotta Sacerdote; Amalia Mattiello; Silke Herman; Rudolf Kaaks; Annika Steffen; Heiner Boeing; Antonia Trichopoulou; Pagona Lagiou; Dimitrios Trichopoulos; Petra H Peeters; Carla H van Gils; Henk van Kranen; Eliv Lund; Vanessa Dumeaux; Dagrun Engeset; Laudina Rodríguez; Maria-José Sánchez; Maria-Dolores Chirlaque; Aurelio Barricarte; Jonas Manjer; Martin Almquist; Bethany van Guelpen; Göran Hallmans; Kay-Tee Khaw; Nick Wareham; Konstantinos K Tsilidis; Kurt Straif; Maria Leon-Roux; Paul Vineis; Teresa Norat; Elio Riboli; H Bas Bueno-de-Mesquita
Journal:  Clin Gastroenterol Hepatol       Date:  2010-10-26       Impact factor: 11.382

View more
  14 in total

Review 1.  Hypoxia driven glycation: Mechanisms and therapeutic opportunities.

Authors:  Mohammad Imran Khan; Suvasmita Rath; Vaqar Mustafa Adhami; Hasan Mukhtar
Journal:  Semin Cancer Biol       Date:  2017-05-22       Impact factor: 15.707

2.  Plasma concentrations of advanced glycation end-products and colorectal cancer risk in the EPIC study.

Authors:  Elom K Aglago; Casper G Schalkwijk; Heinz Freisling; Veronika Fedirko; David J Hughes; Li Jiao; Christina C Dahm; Anja Olsen; Anne Tjønneland; Verena Katzke; Theron Johnson; Matthias B Schulze; Krasimira Aleksandrova; Giovanna Masala; Sabina Sieri; Vittorio Simeon; Rosario Tumino; Alessandra Macciotta; Bas Bueno-de-Mesquita; Guri Skeie; Inger Torhild Gram; Torkjel Sandanger; Paula Jakszyn; Maria-Jose Sánchez; Pilar Amiano; Sandra M Colorado-Yohar; Aurelio Barricarte Gurrea; Aurora Perez-Cornago; Ana-Lucia Mayén; Elisabete Weiderpass; Marc J Gunter; Alicia K Heath; Mazda Jenab
Journal:  Carcinogenesis       Date:  2021-05-28       Impact factor: 4.944

Review 3.  Lysyl Oxidase and the Tumor Microenvironment.

Authors:  Tong-Hong Wang; Shih-Min Hsia; Tzong-Ming Shieh
Journal:  Int J Mol Sci       Date:  2016-12-29       Impact factor: 5.923

Review 4.  Toxic AGE (TAGE) Theory for the Pathophysiology of the Onset/Progression of NAFLD and ALD.

Authors:  Masayoshi Takeuchi; Jun-Ichi Takino; Akiko Sakasai-Sakai; Takanobu Takata; Mikihiro Tsutsumi
Journal:  Nutrients       Date:  2017-06-20       Impact factor: 5.717

5.  Intracellular Toxic Advanced Glycation End-Products Promote the Production of Reactive Oxygen Species in HepG2 Cells.

Authors:  Akiko Sakasai-Sakai; Takanobu Takata; Masayoshi Takeuchi
Journal:  Int J Mol Sci       Date:  2020-07-09       Impact factor: 5.923

Review 6.  Advanced Glycation End Products (AGEs): Biochemistry, Signaling, Analytical Methods, and Epigenetic Effects.

Authors:  Anna Perrone; Antonio Giovino; Jubina Benny; Federico Martinelli
Journal:  Oxid Med Cell Longev       Date:  2020-03-18       Impact factor: 6.543

Review 7.  Serum Levels of Toxic AGEs (TAGE) May Be a Promising Novel Biomarker for the Onset/Progression of Lifestyle-Related Diseases.

Authors:  Masayoshi Takeuchi
Journal:  Diagnostics (Basel)       Date:  2016-06-07

8.  Impact of intracellular glyceraldehyde-derived advanced glycation end-products on human hepatocyte cell death.

Authors:  Akiko Sakasai-Sakai; Takanobu Takata; Jun-Ichi Takino; Masayoshi Takeuchi
Journal:  Sci Rep       Date:  2017-10-27       Impact factor: 4.379

9.  Advanced Glycation End Products Increase MDM2 Expression via Transcription Factor KLF5.

Authors:  Pu Wang; Yu Cheng Lu; Yuan Fei Li; Lan Wang; Shao Chin Lee
Journal:  J Diabetes Res       Date:  2018-09-09       Impact factor: 4.011

Review 10.  Role of Advanced Glycation End Products in Carcinogenesis and their Therapeutic Implications.

Authors:  David Schröter; Annika Höhn
Journal:  Curr Pharm Des       Date:  2018       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.